Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of QIV in India
NCT02451358Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Vaxigrip in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Influenza Vaccine Antibodies, Number of Participants With Seroprotection to Influenza Vaccine Antigens and 1 more. Started Jul 2015; status: completed.
02
Drugs
Vaxigrip
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02451358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451358.